Author

Ana Teijo

Pathology Department MD Anderson Cancer Center Madrid Spain

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:protein structure prediction· 1 Approach:statistical model· 1

Frequent Co-Authors

Alicia Alonso de la VegaiD· 1 shared Ana Monfort‐VengutiD· 1 shared Beatriz Ortigosa· 1 shared Carlos MarugániD· 1 shared Cristina Bertinetti· 1 shared Gema Moreno‐BuenoiD· 1 shared Guillermo de CárceriD· 1 shared María José Lallena· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alicia Alonso de la VegaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivSep 4, 2023

TPX2 expression promotes sensitivity to dasatinib in breast cancer by activating the YAP transcriptional signaling.

Carlos Marugán, Natalia Sanz‐Gómez, Beatriz Ortigosa…·Guillermo de Cárcer

The paper identifies TPX2 as a gene that increases breast cancer sensitivity to dasatinib by activating the YAP pathway, and shows TPX2 and YAP are biomarkers for poor prognosis and potential dasatinib therapy.

DOI 10.1002/1878-0261.13602

humanbulk RNA-seq

𝕏 PostBluesky